Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Clin Pharmacol ; 85(6): 1227-1238, 2019 06.
Article in English | MEDLINE | ID: mdl-30701582

ABSTRACT

AIMS: Cytidine deaminase (CDA) activity in cancer patients' serum has been proposed as a predictive biomarker for efficacy and toxicity of nucleoside analogues. However, discrepant results about its predictive value have been reported due to the high interindividual variability in CDA activity. This study aimed at identifying determinants of this interindividual variability. METHODS: From December 2014 to November 2015, 183 patients were prospectively included. Serum CDA activity, biological and clinical characteristics as well as five common single nucleotide polymorphisms (SNPs) in the CDA gene (c.-451C > T, c.-92A > G, c.-33_-31delC, c.79A > C, c.435 T > C) were analysed. Associations between clinical characteristics, pharmacogenetic variants and CDA activity were univariately tested. P < 0.1-candidate variables were analysed through a multivariate analysis. The association between CDA activity and toxicity was assessed for the 56 gemcitabine-treated patients. Intraindividual variability in CDA activity was explored in six pancreatic cancer patients treated with gemcitabine. RESULTS: Median CDA activity was 3.97 U mg-1 (range 1.53-15.49 U mg-1 ). A univariate analysis showed that CDA activity was statistically associated with Eastern Cooperative Oncology Group performance status, mild or severe malnutrition, inflammatory syndrome, leucocyte count, neutrophil count, albumin, C-reactive protein and -c.-33_-31delC single nucleotide polymorphism. A multivariate analysis identified that only neutrophil count (P < 0.0001) and severe malnutrition (P = 0.0278) were independently associated with CDA activity. Low CDA activity (<2 U mg-1 ) was not statistically associated with severe gemcitabine-related toxicities (P = 0.16). A decrease in CDA activity was observed during the longitudinal follow-up of six pancreatic cancer patients treated with gemcitabine (P = 0.03). CONCLUSIONS: These results suggest that neutrophil count and malnutrition should be considered for the interpretation of pretherapeutic CDA activity.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Biological Variation, Population , Biomarkers, Tumor/blood , Cytidine Deaminase/blood , Deoxycytidine/analogs & derivatives , Drug Monitoring/methods , Pancreatic Neoplasms/drug therapy , Aged , Antimetabolites, Antineoplastic/adverse effects , Biomarkers, Tumor/genetics , Cytidine Deaminase/genetics , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Humans , Inflammation/blood , Inflammation/enzymology , Male , Malnutrition/blood , Malnutrition/enzymology , Malnutrition/physiopathology , Middle Aged , Neutrophils , Nutritional Status , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/enzymology , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Prospective Studies , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL
...